Ignite Creation Date:
2024-05-05 @ 11:40 PM
Last Modification Date:
2024-10-26 @ 10:37 AM
Study NCT ID:
NCT01380587
Status:
COMPLETED
Last Update Posted:
2013-08-27
First Post:
2011-06-22
Brief Title:
Utility of XCL1 as a Prognostic Marker in Acute Lymphoblastic Leukemia
Sponsor:
Hospital Universitario Dr Jose E Gonzalez
Organization:
Hospital Universitario Dr Jose E Gonzalez
Study Overview
Official Title:
Utility of XCL1 as a Prognostic Marker in Acute Lymphoblastic Leukemia
Status:
COMPLETED
Status Verified Date:
2013-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
XCL1
Brief Summary:
The purpose of the study is to determine the utility of XCL1 in the prognosis of acute lymphoblastic leukemia
Detailed Description:
Each year approximately 256000 children and adults around the world develop a form of leukemia and 209000 died from it Recently some studies have evaluated the relationship between the concentration of some cytokines and prognosis of acute lymphoblastic leukemia XCL1 is a lymphotactin that belongs to a cytokine subfamily called C or γ with only one cysteine in the N-terminal residue It has been found with significant expression of receptor mRNA XCL1 XCR1 in T and B lymphocytes and related to hematological neoplasms For these reasons XCL1 could be a efficient marker of prognosis in patients with acute lymphoblastic leukemia
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None